How Eli Lilly Is Making Insulin More Affordable
Eli Lilly has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use its rapid-acting insulin and need a lower-cost option.
Drug companies have been decried in the United States for high prices, but Eli Lilly and Co. (NYSE: LLY | LLY Price Prediction) is looking to fight this trend — at least a little. The pharmaceutical giant has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use Eli Lilly’s rapid-acting insulin and need a lower-cost option.
Now, Eli Lilly’s Insulin Lispro Injection has a 50% lower list price than identical medicine Humalog U-100 and is available in both a vial and KwikPen. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.
Back in March, Eli Lilly announced plans to introduce Insulin Lispro Injection, which fills another gap in the health care system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.
Currently, about 95% of people in the United States pay $95 or less a month for their Humalog prescription, and 43% pay $0 at the retail pharmacy. With the launch of Insulin Lispro Injection, even more people will pay lower amounts at the pharmacy.
Mike Mason, senior vice president, Connected Care and Insulins, commented:
The current healthcare system isn’t working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine. But even one person with diabetes who can’t afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved.
Will this move help Eli Lilly escape the list of America’s most hated companies? In addition, check out 10 things to consider before buying an insulin pen.
Shares of Eli Lilly were last seen at $116.85, in a 52-week range of $81.61 to $132.13. The consensus price target is $124.57.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
